Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis
Clin Exp Dermatol. 2024 Sep 18;49:1232-1234 doi: 10.1093/ced/llae16
Napolitano et al. conducted a retrospective analysis on patients with moderate-to-severe psoriasiform atopic dermatitis (AD) treated with JAK inhibitors, showing significant improvements in disease severity scores (EASI, P-NRS, DLQI) by Week 4, with 95% of patients achieving EASI-75 and 86% achieving EASI-90 by Week 24.
The study retrospectively assessed the clinical effectiveness of JAK inhibitors in treating moderate-to-severe psoriasiform AD over a 24-week period.
